MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
+0.010
+0.77%
Opening 11:00 09/20 EDT
OPEN
1.260
PREV CLOSE
1.300
HIGH
1.390
LOW
1.260
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
3.580
52 WEEK LOW
1.090
MARKET CAP
52.55M
P/E (TTM)
-3.0122
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 08/31 13:32
ATHE, NMTR and PXLW among pre among gainers
GeoVax Labs (NASDAQ:GOVX) +75% presents COVID-19 vaccine data at the European Society of Medicine (ESMED) General Assembly Marin Software MRIN +25% integrates with Criteo's ecommerce media platform for advertising SunLink Health Systems (NYSE:SSY)
Seekingalpha · 08/20 12:21
Benchmark Initiates Coverage On Alterity Therapeutics with Speculative Buy Rating, Announces Price Target of $4
Benchmark analyst Aydin Huseynov initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Speculative Buy rating and announces Price Target of $4.
Benzinga · 08/20 11:27
--Benchmark Starts Alterity Therapeutics at Speculative Buy With $4 Price Target
MT Newswires · 08/20 10:18
26 Stocks Moving in Thursday's Pre-Market Session
Gainers
Benzinga · 08/05 11:00
Sector Update: Health Care
MT Newswires · 08/04 13:38
Alterity Therapeutics' stock jumps 18% on new U.S. patent for Alzheimer's/Parkinson's
The USPTO has issued a Notice of Allowance for Alterity Therapeutics' (NASDAQ:ATHE) patent application No. 17/239,375. ATHE shares surge 17.5% premarket to $1.61. The composition of matter patent secures exclusivity for a new
Seekingalpha · 08/04 12:47
ATVI, MGM and MNKD among pre market gainers
BeyondSpring BYSI +336% Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Seekingalpha · 08/04 12:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHE. Analyze the recent business situations of Alterity Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHE stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 1.01M
% Owned: 2.51%
Shares Outstanding: 40.11M
TypeInstitutionsShares
Increased
3
18.16K
New
3
64.93K
Decreased
1
27.03K
Sold Out
1
69.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.23%
Pharmaceuticals & Medical Research
-0.66%
Key Executives
Non-Executive Chairman
Geoffrey Kempler
Chief Executive Officer
David Stamler
Chief Financial Officer
Kathryn Andrews
Secretary
Phillip Hains
Non-Executive Director
Tristan Edwards
Non-Executive Director
Lawrence Gozlan
Non-Executive Director
David Sinclair
Non-Executive Independent Director
Peter Marks
Non-Executive Independent Director
Brian Meltzer
No Data
  • All
  • Financials
  • Insiders
More
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.

Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.